Core Insights - Labcorp reported revenue of $3.35 billion for the quarter ended March 2025, reflecting a year-over-year increase of 5.3% [1] - The company's EPS was $3.84, up from $3.68 in the same quarter last year, exceeding the consensus estimate of $3.73 by 2.95% [1] - The revenue fell short of the Zacks Consensus Estimate of $3.41 billion, resulting in a surprise of -2.04% [1] Financial Performance Metrics - The net book-to-bill ratio was reported at 1.1%, surpassing the estimated 1% by analysts [4] - Revenue from Biopharma Laboratory Services was $721.30 million, below the average estimate of $742.69 million, but showing a year-over-year increase of 1.5% [4] - Revenue from Diagnostics Laboratories was $2.63 billion, compared to the average estimate of $2.69 billion, with a year-over-year increase of 6.1% [4] - Adjusted Operating Income for Biopharma Laboratory Services was $106.90 million, slightly below the estimated $108.86 million [4] - Adjusted Operating Income for Diagnostics Laboratories was $427.50 million, compared to the average estimate of $435.69 million [4] Stock Performance - Labcorp's shares have returned -1.4% over the past month, while the Zacks S&P 500 composite has changed by -0.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]